ALP Bio raises €161K from Venture Kick to improve the safety of biologic medicines
Swiss biotechstartup ALP Bio has secured €161,000 (CHF 150,000) from Venture Kick to supportthe commercial development of its platform, which helps drug developersidentify immune-related risks earlier...
The increasing complexity of biologic medicines necessitates advanced methods for early safety assessment to accelerate drug development and reduce costs, driving innovation in this space.
This development indicates continued investment and progress in synthetic biology applications for drug safety, potentially reducing clinical trial failures and speeding up access to new therapies.
Drug developers gain a new tool to identify immune-related risks earlier in the pipeline, potentially making the development of biologic medicines safer and more efficient.
- · ALP Bio
- · Biotech companies developing biologics
- · Patients needing new biologic medicines
- · Venture Kick
- · Traditional drug safety assessment methods
- · Companies without advanced risk-identification platforms
ALP Bio will proceed with commercial development and broader adoption of its platform for biologics safety.
The increased efficiency in identifying early risks could lead to a higher success rate for biologic drug candidates in clinical trials.
More predictable and efficient biologic drug development could encourage further investment and innovation in the broader advanced therapeutics sector.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Tech.eu